HHS In Final Phases Of Acquiring Additional Countermeasures Under BioShield
This article was originally published in The Pink Sheet Daily
Executive Summary
Department is nearing contract completion for anthrax therapeutics, botulinum antitoxin and a next-generation smallpox vaccine. HHS has awarded three contracts since passage of BioShield legislation, for recombinant protective antigen anthrax vaccine, potassium iodide and anthrax vaccine adsorbed.